Therapeutic effects of the losartan combined with atorvastatin on the patients with diabetic nephropathy
10.3760/cma.j.issn.1008-1372.2012.11.014
- VernacularTitle:氯沙坦联合阿托伐他汀治疗糖尿病肾病的疗效观察
- Author:
Jing LI
;
Ruizhu HUANG
- Publication Type:Journal Article
- Keywords:
Losartan/therapeutic use;
Heptanoic acids/therapeutic use;
Pyrroles/therapeutic use;
Diabetic nephropathies/drug therapy
- From:
Journal of Chinese Physician
2012;(11):1490-1492
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the therapeutic effects of the losartan combined with atorvastatin on patients with diabetic nephropathy (DN).Methods 122 patients with DN were randomly divided into two groups,61 cases in the control group were received conventional therapy and added the losartan,61 cases in the observation group were treated by atorvastatin on the basis of the control group.The treatment time was 12weeks for each group.After 12 weeks,the systolic blood pressure (SBP),diastolic blood pressure (DBP),triglycerides (TG),total cholesterol (TC),low-density lipoprotein cholesterol (LDL-C),high density lipoprotein cholesterol (HDL-C),fasting blood glucose (FBG),urinary albumin excretion rate (UAER),serum creatinine (Scr),and glycosylated hemoglobin (HbAIc) were measured.Results The total effective rate was 93.44％ in the observation group,and 75.41％ in the control group,with a statistically significant difference between two groups (x2 =7.54,P ＜ 0.01).After 12 weeks,the SBP and DBP were all changed more than before,DBP decreased more significantly (SBP:t =16.25,17.34,P ＜0.01 ;DBP:t =18.10,17.04,P ＜0.01); FBG,UAER,and HbAlc in the control group were significantly reduced (P ＜ 0.05) ; the TG,TC,LDL,-C HDL,-CFBG,UAER,Scr,and HbAlc of the observed group were significantly reduced more,too.TG,TC,UAER,and Scr of the observed group were significantly lower than the control group (P ＜ 0.05).Conclusions The losartan combined with atorvastatin that were used to treat patients with DN can reduce the urine albumin and protect the renal function.
